business
Galderma Shares Slump After FDA Turns Down Botox Rival Relfydess
Galderma Group AG shares slumped the most in more than a year after the Swiss dermatology firm said the US Food and Drug Administration had turned down its rival Botox treatment Relfydess.
Read full story on Bloomberg Markets → More top storiesAlso covered by
Aggregated and edited by the Scoop newsroom. We surface news from Bloomberg Markets alongside other reporting so you can compare coverage in one place.
Editorial policy · Corrections · About Scoop